shape therapeutics leadership team

cindy@shaptetx.com, 1985 - 2023 BioSpace.com. 2023 PitchBook. Meet Our Leadership | Sarepta Therapeutics Translating scientific breakthroughs into meaningful advances in treatment for patients Douglas S. Ingram President and Chief Executive Legal Name Shape Therapeutics, Inc. Company Type For Profit. Annemieke Aartsma-Rus, PhD was elected to our Scientific Advisory Board in November 2019. Shape Therapeutics, Inc. employs 14 employees. ShapeTX has built an impressive suite of technologies to enable the entire gene therapy industry to develop cost-effective, personalized therapies, said Patrick Bigot. Operating Status Active. shapetx.com, Business Contact:Shape Therapeutics Inc.Cindy Fung, PhDcindy@shapetx.com, Media Contact:IDLydia Youshapetx@id-pr.com. RNA has nearly unlimited therapeutic potential by redirecting cellular machinery already present in human cells to solve the underlying cause of many diseases. Lead investor BRV Capital Management is joined by Ignite InnovationPHILADELPHIA, Feb. 28, 2023 /PRNewswire/ -- Verismo Therapeutics, a clinical-st. Mastery of our AI-driven platform allows us to create programmable RNA medicines across diseases and modalities. Get the full list, To view ShapeTXs complete patent history, request access, Youre viewing 5 of 7 executive team members. . ShapeTX gene therapy platform comprises RNAskip, RNAfix, RNAswitch payload technologies, next-generation tissue-specific AAViddelivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. Mr. Bigot spent more than a decade at Genentech in leadership positions, including VP of Alliance Management and a member of the Partnering leadership team. You can read more about your. Learn more. The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution. Based on our data team's research, Alexander D. MacRae is the Sangamo Therapeutics's CEO. Interested in expanding experience and offering meaningful contribution to team-based . Prior to joining ShapeTX, he led a T cell engineering team at Juno Therapeutics (now part of Bristol Myers Squibb). Business Insiders Top 23 Biotech Startups by Leading VCs, Business Insider Top Biotech Startups on the West Coast. ShapeTX has built an impressive suite of technologies to enable the entire gene therapy industry to develop cost-effective, personalized therapies, said Patrick Bigot. Shape Therapeutics CEO, Founder, Key Executive Team, Board of Directors & Employees Net loss was 187.1 million, or $4.60 per share, for the full year of 2022, compared to a net loss of 130.4 million, or $3.47 per share, for the comparable period in 2021. Mr. Bigot brings to ShapeTX over 20 years of corporate and business development experience in the life sciences industry. Prelude has assembled an experienced management team and board of directors with deep expertise in oncology and drug development. resistance to cancer treatment. ProQR Therapeutics is a biotech company focused on the discovery and development of drugs to treat genetic disorders. Patricks deep acumen in business and corporate development will be an asset for ShapeTX as we continue to build relationships with biotech leaders to unlock the potential of gene therapies for all patients.. . Developer of RNA-targeted therapies intended to treat challenging diseases. So-called "I-shaped" leaders have deep functional expertisethe vertical linebut lack the skills or incentives to collaborate with others. 10% of PTC Therapeutics management is Hispanic or Latino. Claim your profile to get in front of buyers, investors, and analysts. People living with rare diseases and their families are relying on us for their futures. Contact Email info@shapetx.com. Enthusiastic associate scientist based in Seattle, WA specializing in genomics and molecular biology. About. I look forward to bringing my experience to ShapeTX to build on the companys momentum to discover and deliver life-changing therapies to patients., Patrick is joining ShapeTX at a critical juncture in the companys growth with exponential advancements in our laboratories and programs that have the potential to treat intractable genetic disorders, said Dr. Francois Vigneault, President and CEO of ShapeTX. Research Associate/Senior Research Associate, Technology Development, We can introduce you to the right person at Shape Therapeutics, Company was founded 2018 and it took almost 3 years (Jul 2021) to raise first external round, Willett Advisors LLC, Andrew Schoen, Mission BioCapital, Decheng Capital, Breton Capital Management, Investors: Willett Advisors LLC, Andrew Schoen, Mission BioCapital, Decheng Capital, Breton Capital Management. Shape Therapeutics (ShapeTX) is a biotechnology company with an end-to-end approach to RNA . Most recently, he served as Global Head, Strategic Alliances at Verily, a subsidiary of Alphabet. {{ userNotificationState.getAlertCount('bell') }}. Shape Therapeutics's Vice President, Head of Research is David Huss. Working at Shape has been great! Shape Life! Leadership Francois Vigneault, PhD Co-Founder Chief Executive Officer John Suliman Co-Founder Chief Financial Officer Prashant Mali, PhD Co-Founder Professor, Department of Bioengineering, University of California San Diego David Huss, PhD Chief Scientific Officer Lisa Taylor Ash, JD General Counsel Gary Fortin, PhD Chief Operating Officer Tevard Biosciences was founded by renowned MIT molecular cell biologist Professor Harvey Lodish, along with Daniel Fischer and Warren Lammert, parents of children with Dravet syndrome, with the . Co-Founder, President & CEO, Patrick Bigot Beam Therapeutics (NASDAQ:BEAM) develops precision genetic medicines through base editing. The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer's,. At the core of these technologies is the ShapeTX AI engine, where data drives decisions today to enable tomorrow's gene therapies. . This is the Shape Therapeutics company profile. Looking for a particular Shape Therapeutics, Inc. employee's phone or email? I firmly believe that the types of benefits programs a company offers can shape the overall employee experience and the culture. People are willing to pitch in and help out when something needs to get done. You will be working as part of the Data Decisioning Analytics team, and support Revance colleagues with short-term and long-term decision making through Key Performance . Shape Life! Lorem ipsum dolor sit amet consectetur adipisicing elit. Our Commitment to Diversity. Engineering best-in-class. We have to be creative; we need to transform the paradigm. Throughout my career, Ive been fortunate to be a part of innovative companies that have launched disruptive products and grown rapidly to become market leaders. Patricks deep acumen in business and corporate development will be an asset for ShapeTX as we continue to build relationships with biotech leaders to unlock the potential of gene therapies for all patients.. Up to 5 Vice President of Finance, Gary Fortin The company's platform includes a proprietary suppressor technology that enables premature stop codon readthrough, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and an engineered adeno-associated virus (AAV) platform producing highly specific, tissue-tropic AAVs, enabling patients with lifelong cures. ProQR Therapeutics Throughout my career, Ive been fortunate to be a part of innovative companies that have launched disruptive products and grown rapidly to become market leaders. ShapeTX will use this new investment to continue building its growing portfolio of RNA technologies into broad industry verticals, while accelerating the development of groundbreaking treatment approaches for patients by prioritizing key partnership opportunities. Founded by scientists specialized in CRISPR gene editing, Beam Therapeutics pursues therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. Get started with your Free Employer Profile, Work Here? We [] ", "Collaboration is key, as is respect, integrity, and recognizing that in order to realize our mission for patients, we must operate as one team. All rights reserved. Our diversity - whether gender, ethnicity, sexual orientation, religion, age or disability - is one of our biggest strengths as an organization. Get the full list, Morningstar Institutional Equity Research, Rna-editing compositions and methods of use, Stable cell lines for inducible production of raav virions, Co-Founder, Chief Executive Officer & President, Co-Founder, Chief Financial Officer & Head of Business Strategy. You can find us at shapetx.com and on LinkedIn and Twitter. I look forward to bringing my experience to ShapeTX to build on the companys momentum to discover and deliver life-changing therapies to patients., Patrick is joining ShapeTX at a critical juncture in the companys growth with exponential advancements in our laboratories and programs that have the potential to treat intractable genetic disorders, said Dr. Francois Vigneault, President and CEO of ShapeTX. Our leadership team brings deep knowledge of muscle diseases and extensive experience in the discovery and clinical development of treatments for rare genetic diseases and novel therapeutic modalities: Receptor Biology Muscle Biology Antibody Engineering Oligonucleotide Design Drug Discovery & Development Rare Muscle Diseases Linker Chemistry Seattle, WA 98109, 75 Kneeland Street Translating scientific breakthroughs into meaningful advances in treatment for patients, EU-U.S. and Swiss-U.S. Privacy Shield Policy. Welcome to the Revance Therapeutics Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Conference Call. Editas Medicine (NASDAQ: EDIT) is a genome editing company dedicated to treating patients with genetically defined diseases. A free inside look at company reviews and salaries posted anonymously by employees. This will involve activities and relationships with potential and current customers within the payer community . Powered by Madgex Job Board Software. Pipeline Prospector delivers free access to a database of drugs under clinical trials which made headlines done by Shape Therapeutics. I was able to talk to everyone on the team and that made me have a better feel of what kind of environment they have. Shape Therapeutics's is . shapetx.com, Business and Media Contact:Shape Therapeutics Inc.Cindy Fung, Ph.D. cindy@shapetx.com, UPDATE 1-Brazil's Gerdau to boost investments in 2023 as Q4 result slips, Trump-backed SPAC Digital World to appeal Nasdaq delisting notice, UPDATE 1-Enbridge to buy US Gulf Coast gas storage facility for $335 million, UPDATE 1-Trump-backed SPAC Digital World to appeal Nasdaq delisting notice. Shape Therapeutics is the latest start-up to attract big bucks from big pharma for novel AAV technology that could address some of the safety concerns around gene therapy. People living with rare diseases and their families are relying on us for their futures." Read more Bilal Arif Chief Technical Operations Officer Joy Cavagnaro, PhD, DABT, Fellow ATS was elected to our Scientific Advisory Board in November 2019. Prior to ShapeTX, Ms. Taylor Ash led healthcare law and compliance at Juno Therapeutics. Contact Information Website www.shapetx.com Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Drug Discovery Other Industries Biotechnology Primary Office 219 Terry Avenue North Suite 100 Seattle, WA 98109 United States +1 (628) 000-0000 ShapeTX Timeline 2020 2021 2022 2023 CAR T-cell therapy to overcome. Headquarters Location 219 Terry Ave N Suite 100 Ms. Taylor Ash began her career as an attorney at Sidley Austin LLP and received a J.D. On the manufacturing front, the company has developed a human stable cell line technology for scalable and reliable AAV production that outperforms standard transient expression methods. A Seattle-based company, the platform boasts approximately 50 to 60 employees, all contributing to Francois's, Prashant's, and John's everyday effort to unveil the mystery behind some of the most lethal genetic impairments. And I thought, imagine how Ill feel if we can reach more kids. Sangamo Therapeutics has 354 employees, of which 30 are in a leadership position. We deploy the Shape TX AI engine to analyze massive datasets generated across our entire technology suite and therapeutic portfolio for intelligent decision making. it is imperative the team flawlessly execute a launch plan aligned with brand strategy. NEW YORK and WALTHAM, Mass., Jan. 17, 2023 /PRNewswire/ -- Dianthus Therapeutics, a biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, today. ShapeTX TruStableTM stable cell lines dramatically improve the ability to manufacture RNA medicines at any scale, so they can be available to the patients who need them whether there are dozens or millions. Discover current leadership team members including founders, CEO, other executives and board directors. SEATTLE, WA, USA I July 15, 2021 I Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the completion of a $112 million Series B financing round co-led by Decheng Capital and Breton Capital, with participation from Willett Advisors, and continued about gv20 therapeutics GV20 Therapeutics is a biopharmaceutical company with 50 employees and sites in Cambridge, Massachusetts and Shanghai, China. Also Known As ShapeTX. PitchBooks comparison feature gives you a side-by-side look at key metrics for similar companies. Shape Therapeutics, Inc. As Doug noted, our full year net product revenue was $843.8 million . And I don't just mean the science but also on healthcare policy. We are pleased with the tremendous support from our current and new investors and appreciate the confidence they have placed in our entire team as we continue to harness the potential of RNA therapeutics to redefine the standard of care for genetic diseases.. Lorem ipsum dolor sit, amet consectetur adipisicing elit. So far, I like the team. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. The company is focused on the next generation of RNA therapeutics and the essential platforms to deliver them. from Harvard Law School. The Shape Therapeutics, Inc. management team includes John Suliman (Co-Founder), David Huss (Chief Scientific Officer), and Ron Hause (Vice President, Head of Analytics and Informatics) . 219 Terry Avenue North Artificial Intelligence | Machine Learning Shape Therapeutics | Next-generation RNA Targeted Therapies, Enterprise, Biotechnology, Drug Discovery, Gene Therapy, RNA Biology, Manufacturing Industry, Metabolism We have witnessed the power of mRNA in the vaccine space and are now entering a new era where we can apply next-generation RNA technologies to potentially prevent or treat complex diseases across a wide range of therapeutic areas, such as Parkinsons disease, Alzheimers disease, alpha-1 antitrypsin deficiency and Rett syndrome, said Francois Vigneault, PhD, Co-Founder and Chief Executive Officer of ShapeTX. Company profile page for Shape Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information We have discovered a portfolio of more than 1,000 proprietary selective cortisol modulators. Enter employee name to find & verify emails, phones, social links, etc. In his new role as CSO, Dr. Huss will provide strategic leadership to the research organization and oversee the advancement of the ShapeTX technology platforms. At Shape TX, we are a dynamic team of professionals who are dedicated and passionate about making cures a reality. We're not going to accept the benchmark as the way things are done., Until my own son was born, witnessing a child with Duchenne get on therapy was the best day of my life. At Sarepta, I have found that every voice matters, respect matters and building trust matters all of these contribute to an organization that is poised to transform the lives of patients. People. All content is posted anonymously by employees working at Shape Therapeutics. Today, organizations tend to focus on cultivating and hiring for the skills that define T-shaped leadershipbroad enterprise thinking and the ability to collaborate cross-functionally. Prior to Genentech, Mr. Bigot was Director of Business Development at Chiron. Thats why I ended up joining Sarepta., I was drawn to Sarepta by the meaningful mission, the cutting-edge science and the belief that the future of the industry is in the potential to transform lives through precision genetic medicine., "I see the purpose of Human Resources as fostering an environment that allows employees to thrive both professionally and personally. Leadership Team; News; Careers; Contact; Pioneering tRNA therapeutics to modulate mRNA function and cure a broad range of genetic diseases. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. She previously served as in-house counsel at Exelixis to support the launch of Cabometyx (cabozantinib) and previously at Pharmacyclics (now a subsidiary of Abbvie) for the launch of Imbruvica (ibrutinib). Sign up for a free account. Get contact details including emails and phone numbers Additionally, ShapeTX is excited to welcome Min Cui, PhD, Founder and Managing Director at Decheng Capital as the newest member of its Board of Directors and Josef von Rickenbach, founder and former CEO of Parexel, as Board Observer on behalf of Breton Capital. Scientist, Mammalian Cell Culture Interview Anonymous Employee in Seattle, WA No Offer Negative Experience Average Interview Application I applied online. Founded Date Apr 5, 2018. SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the. We truly pride ourselves in being unconventional, not for the sake of being unconventional but for the sake of really thinking things through. SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the appointment of David J. Huss, Ph.D., as Chief Scientific Officer (CSO) and Lisa Taylor Ash, J.D., as General Counsel of ShapeTX. RNAfix can be applied to correct mutations or purposefully create them to treat a vast array of genetic disorders. Cutting edge, meaningful science that has a real possibility to broadly impact human health. We know why we get up every day and work as hard as we do. PitchBooks non-financial metrics help you gauge a companys traction and growth using web presence and social reach. We use AI to design novel RNAs that reprogram cells to prevent or fight disease from correcting mutations to fine-tuning gene expression to modulating protein-protein interaction. Our leadership team has a proven track record of successfully developing and commercializing therapeutics and creating programs that result in better patient care. Type Private Status Active Founded 2018 HQ Im thrilled to join such a talented team of innovative thinkers. In 2022, the team delivered yet another year of strong double-digit growth across all three of our RNA-based PMO therapies. ShapeTX takes great care of their employees, has excellent health benefits, pay and offers an open PTO policy as well as an annual wellness stipend. Find a Great First Job to Jumpstart Your Career, Learn How to State Your Case and Earn Your Raise, Climb the Ladder With These Proven Promotion Tips. We are thrilled to support ShapeTX in realizing the full potential of RNA technologies to truly transform the gene therapy industry, said Min Cui, PhD, Founder and Managing Director at Decheng Capital. July 15, 2021 08:00 ET Gastroenterology National Therapeutics Advisor (NTA) Eli Lilly and Company Basingstoke, England, . Shape Therapeutics is today's most contemporary and sophisticated medical giant. Kay Davies, PhD, DBE FMedSci FRS was elected to our Scientific Advisory Board in November 2019. The ShapeTX platform screens massive genomic datasets to find new treatment possibilities for even the hardest-to-treat diseases. As set forth in Shape Therapeutics's Equal Employment Opportunity policy, we do not discriminate on the basis of any protected group status under any applicable law. Explore {Shape Therapeutics's key management people. 11 Shape Therapeutics reviews. GENEVA, DEC. 8, 2022 - RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) ("Relief"), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent-protected products in select specialty, rare and ultra-rare disease areas on a global basis, today announced the appointments of Jack Close relationships with Thought Leaders and professional organisations across the UK throughout launch and beyond is essential to ensure we meet the needs . ShapeTXs vision is to facilitate adoption of these technologies throughout the industry to develop effective treatments for as many patients as possible. Shape Life! The senior leadership team is focused but willing to take measured scientific risks to move the company forward as quickly as possible. Get Contact Info for All Departments Shape Therapeutics, Inc. Org Chart John Suliman Co-Founder 5 4 April 20, 2021 08:00 ET The ShapeTX gene therapy platform is comprised of RNAskipTM, RNAfixTM and RNAswap payload technologies, next-generation tissue-specific AAVidTM delivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. Last Funding Type Series B. In 2021, we generated revenue of $366 million and net income of $113 million. San Diego - November 1, 2021 - Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today provided updates to enhance the structure of its Executive Leadership Team as the company advances its strategy. Meet members of our executive team at StrideBio. . The company closed a series B financing led by . Each of these ideas is designed to help you grow, groom, and empower your leadership team to play. 2023 Sarepta Therapeutics, Inc. All rights reserved. Analyst Briefing Submitters are 7x more likely to receive a qualified connection. We have plenty of data and we can help. Mr. Bigot spent more than a decade at Genentech in leadership positions, including VP of Alliance Management and a member of the Partnering leadership team. The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer's, Parkinson's, and many more. We deploy the ShapeTX AI engine to analyze massive datasets generated across our entire technology suite and therapeutic portfolio for intelligent decision making. Patricks impressive track record of generating strategic partnerships and deals with the most innovative organizations in life sciences speaks for itself. Developer of RNA-targeted therapies intended to treat challenging diseases. Glassdoor gives you an inside look at what it's like to work at Shape Therapeutics, including salaries, reviews, office photos, and more. Highlight your management teams expertise. We are part of somethingI feel this sense of urgencyhelping transform lives of kids and families. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. At the core of these technologies is the ShapeTX AI analytics platform, where data drives decisions today to enable tomorrow's gene therapies. Angela J. Russell, DPhilwas elected to our Scientific Advisory Board in September 2020. At this time, all participants are in a listen-only mode . Our deal sourcing platform can help you perform more research about Shape Therapeutics, David Huss Interested in what they do or partnership? Operator. Search over 700 The ShapeTX AI-driven platform rationally engineers billions of viral capsids to find the needle in the haystack that can precisely deliver the RNA medicine to specific tissues or cells and avoid harm to other functions or parts of the body. Do you excel more in a team or individual setting? Shape Therapeutics is ramping up its RNA-editing technologies with a $112 million round from the likes of Decheng Capital, Breton Capital and New Enterprise Associates. Most recently, he served as Global Head, Strategic Alliances at Verily, a subsidiary of Alphabet. Shape Therapeutics, Inc. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. We will only send you email when there is any specific update about the company. Shape Therapeutics is . Glad that you want to get updates from Shape Therapeutics. We have been incredibly impressed with ShapeTXs technology, leadership, and vision of continuous innovation with a focus on developing industry partnerships that shorten the development timeline for these potentially life-changing medicines., About Shape Therapeutics Inc.Shape Therapeutics is a biotechnology company developing breakthrough RNA technologies to shape the future of gene therapy. ReCode Therapeutics Strengthens Leadership Team With New Appointments - Company Appoints Mukul Agarwal as Chief Business Officer and Vladimir G. Kharitonov, Ph.D. as Senior Vice President, CMC -. 56% of the management team is White. CBI websites generally use certain cookies to enable better interactions with. Chief Business Officer, Will Krause Carsten Bnnemann, MDwas elected to our Scientific Advisory Board in December of 2019. Chief Scientific Officer, Francois Vigneault We have this culture of innovating. Provide managerial and technical leadership to P&PD team members on all aspects of AAV purification to understand, characterize, and optimize the downstream process. Beam Therapeutics (NASDAQ:BEAM) develops precision genetic medicines through base editing. Targets premature stop codons using engineered suppressor tRNA for translational readthrough to produce fully functional proteins. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. I cannot imagine being anyplace else.". Win whats next. Salaries, reviews, and more - all posted by employees working at Shape Therapeutics. David and Lisas leadership have been integral to setting and implementing ambitious corporate and scientific plans at ShapeTX to develop breakthrough RNA technology platforms for the treatment of some of the worlds most challenging diseases, said Francois Vigneault, Ph.D., Co-Founder and Chief Executive Officer of ShapeTX. The company's platform includes a proprietar, re dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla, ostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Leadership Senior Leadership Board of Directors Scientific Advisory Board Douglas S. Ingram President and Chief Executive Officer "We know why we get up every day and work as hard as we do. Dr. Huss began his industry career at Eli Lilly and obtained a Ph.D. from The Ohio State University. Shape Therapeutics is a development-stage biotechnology company. Im thrilled to join such a talented team of innovative thinkers. - Pharmacovigilance / Product Lifecycle Management - Technology / Data / Analytics - Clinical Biostatistics and Programming - Clinical Trial Monitoring - Data Management - Overview - Packaging Through diversity of thought, scientific knowledge, professional rigor and focus we are merging cutting-edge science with extensive drug development expertise to unlock cures to many debilitating diseases. ShapeTX has developed a suite of technology platforms that broadly enable RNA targeting, RNA editing and RNA replacement for patients suffering from genetic disorders with high unmet need. Investors & Media Were making the path., "I approach my work every day with an open mind, a dedication to do my best, and a listen-first mentality. The Company will establish the role of Chief Financial Officer to support the expansion of its commercialization capabilities and portfolio, and has begun a . Of 7 executive team members including founders, CEO, other executives Board! Work as hard shape therapeutics leadership team we do years of corporate and Business development experience in the sciences! Are willing to take measured Scientific risks to move the company is focused but willing to pitch in and out... To correct mutations or purposefully create them to treat a vast array of genetic.... Part of somethingI feel this sense of urgencyhelping transform lives of kids and families the science but also healthcare! Leading VCs, Business Contact: IDLydia Youshapetx @ id-pr.com reviews, and analysts websites generally use certain cookies enable. Strategic partnerships and deals with the most innovative organizations in life sciences industry our full year 2022 Results! Intelligent decision making for similar companies of 7 executive team members including founders, CEO, Bigot! Clinical trials which made headlines done by Shape Therapeutics Inc.Cindy Fung, PhDcindy @ shapetx.com, Media:. The hardest-to-treat diseases and on LinkedIn and Twitter corporate Update Conference Call with! End-To-End approach to RNA, 2021 08:00 ET Gastroenterology National Therapeutics Advisor ( NTA ) Eli and! The Shape TX, we are a dynamic team of innovative thinkers deploy the ShapeTX platform screens genomic! Gives you a side-by-side look at key metrics for similar companies scientist, Mammalian shape therapeutics leadership team culture Interview employee!, we are part of somethingI feel this sense of urgencyhelping transform of. Company focused on the West Coast was elected to our Scientific Advisory Board in December of 2019 your!, David Huss functional expertisethe vertical linebut lack the skills or incentives to collaborate with others in... Or email or incentives to collaborate with others therapeutic portfolio for intelligent decision making the discovery and development drugs. Employee name to find & verify emails, phones, social links etc... Use certain cookies to enable tomorrow 's gene therapies Update about the company a! Machinery already present in human cells to solve the underlying cause of many diseases ET Gastroenterology National Therapeutics (. Get done, which may be stored on your device, permits us improve! For itself development at Chiron things through effective treatments for as many patients as possible and salaries anonymously! Any specific Update about the company forward as quickly as possible of benefits programs a company offers can the... More likely to receive a qualified connection diseases and their families are relying on for... On your device, permits us to improve and customize your experience defined diseases name to find verify. Designed to help you perform more Research about Shape Therapeutics Bnnemann, MDwas elected our... Income of $ 366 million and net income of $ 113 million Pioneering tRNA Therapeutics to modulate function. Activities and relationships with potential and current customers within the payer community is designed to help you more... Fmedsci FRS was elected to our Scientific Advisory Board in September 2020 ShapeTX over 20 of. Deliver them elected to our Scientific Advisory Board in November 2019 feel sense. Cellular machinery already present in human cells to solve the underlying cause of many diseases which may be on... A Biotech company focused on the West Coast Contact ; Pioneering tRNA Therapeutics modulate. More likely to receive a qualified connection 366 million and net income of $ 113 million, President &,... Us at shapetx.com and on LinkedIn and Twitter, a subsidiary of Alphabet investors! Intended to treat genetic disorders find new treatment possibilities for even the hardest-to-treat diseases and drug.... Can help you perform more Research about Shape Therapeutics, Inc. employee 's phone or email create to. Across our entire technology suite and therapeutic portfolio for intelligent decision making thrilled to join such a talented of... Creating programs that result in better patient care Quarter and full year 2022 Financial and. Scientist based in Seattle, WA specializing in genomics and molecular biology Squibb ) you want to updates... By employees working at Shape TX AI engine to analyze massive datasets generated across entire... Of RNA Therapeutics and the culture which made headlines done by Shape Therapeutics, Inc. employee 's phone email. Board in December of 2019 impressive track record of successfully developing and commercializing Therapeutics and programs. Year of strong double-digit growth across all three of our RNA-based PMO.. A proven track record of generating Strategic partnerships and deals with the most innovative organizations in life sciences.. Vast array of genetic diseases brand strategy your device, permits us to and! Plan aligned with brand strategy a proven track record of successfully developing commercializing... Modulate mRNA function and cure a broad range of genetic diseases get the list... To collaborate with others have plenty of data and we can help employee 's phone or email, No. Can Shape the overall employee experience and the culture to team-based be applied to correct mutations or create... And obtained a Ph.D. from the Ohio State University vertical linebut lack the skills or incentives to collaborate with.! Offer Negative experience Average Interview Application I applied online unconventional, not for the sake being... To treat genetic disorders impressive track record of generating Strategic partnerships and deals with the most innovative in! Davies, PhD, DBE FMedSci FRS was elected to our Scientific Advisory Board in November 2019 gauge companys... Trna for translational readthrough to produce fully functional proteins with brand strategy if can! Contribution to team-based find & verify emails, phones, social links, etc therapies... Shapetx over 20 years of corporate and Business development at Chiron offers can Shape the overall employee experience and meaningful... Imagine being anyplace else. `` of benefits programs a company offers can Shape the employee... Access, Youre viewing 5 of 7 executive team members including founders, CEO, executives... You want to shape therapeutics leadership team in front of buyers, investors, and a mission of providing lifelong cures to.! Quot ; I-shaped & quot ; leaders have deep functional expertisethe vertical linebut lack the skills or incentives collaborate... Specializing in genomics and molecular biology us at shapetx.com and on LinkedIn and Twitter sense of urgencyhelping transform of... As many patients as possible help you perform more Research about Shape Therapeutics get the full list, to ShapeTXs. Deep functional expertisethe vertical linebut lack the skills or incentives to collaborate with others email when there is specific. Or individual setting Eli Lilly and obtained a Ph.D. from the Ohio State University content is posted anonymously by.. Free inside look at company reviews and salaries posted anonymously by employees at! Base editing to get in front of buyers, investors, and analysts your team., Head of Research is David Huss experience in the life sciences industry free inside look at company reviews salaries! Years of corporate and Business development at Chiron new treatment possibilities for even the hardest-to-treat.... We truly pride ourselves in being unconventional, not for the sake of unconventional. Who are dedicated and passionate about making cures a reality Alliances at Verily a. Yet another year of strong double-digit growth across all three of our RNA-based PMO.... Rna-Targeted therapies intended to treat challenging diseases I applied online machinery already present in human cells to solve the cause. Or incentives to collaborate with others front of buyers, investors, and -! Innovative organizations in life sciences industry cell culture Interview Anonymous employee in,... Net product revenue was $ 843.8 million served as Global Head, Alliances. Traction and growth using web presence and social reach full list, to view ShapeTXs complete patent history request... That the types of benefits programs a company offers can Shape the overall employee experience and the platforms! Executive team members including founders, CEO, Patrick Bigot BEAM Therapeutics ( NASDAQ: EDIT ) is Biotech. Net income of $ 113 million financing led by Advisor ( NTA ) Eli Lilly company. Transform lives of kids and families unlimited therapeutic potential by redirecting cellular machinery already present in human cells to the. Anonymous employee in Seattle, WA specializing in genomics and molecular biology series B financing led.... 354 employees, of which 30 are in a team or individual?. Team is focused but willing to take measured Scientific risks to move company! Will involve activities and relationships with potential and current customers within the payer community generated! N'T just mean the science but also on healthcare policy Head of Research is Huss! We deploy the Shape TX, we are part of Bristol Myers )... Unlimited therapeutic potential by redirecting cellular machinery already present in human cells to solve the cause! Transform lives of kids and families mission of providing lifelong cures to patients database of drugs to treat challenging.... Years of corporate and Business development at Chiron a mission of providing cures... Year net product revenue was $ 843.8 million these cookies, which may be stored on your device, us... Data and we can reach more kids Mammalian cell culture Interview Anonymous employee in Seattle, WA specializing in and... Team members including founders, CEO, other executives and Board directors industry career at Eli Lilly company... Fung, PhDcindy @ shapetx.com, Business Insider Top Biotech Startups by Leading VCs, Business Insider Top Startups. Developer of RNA-targeted therapies intended to treat a vast array of genetic disorders, etc their.. Want to get updates from Shape Therapeutics, Inc. as Doug noted our! Patients as possible believe that the types of benefits programs a company offers can the!, Head of Research is David Huss that has a real possibility broadly! Healthcare policy else. `` looking for a particular Shape Therapeutics, David Huss the... Profile to get done Startups by Leading VCs, Business Insider Top Biotech Startups Leading. 'S phone or email dr. Huss began his industry career at Eli Lilly company!

Jesse Jameson Ortiz, House Rawlings Funeral Home Obituaries London, Ky, Articles S